Пробиотики в педиатрии: за и против с позиции доказательной медицины


https://doi.org/10.21508/1027-4065-2016-61-1-17-23

Полный текст:


Аннотация

Представлены современные данные о проблеме изучения микробиоты кишечника, дана классификация представителей микрофлоры кишечника, описаны ее позитивные и негативные функции. С клинических позиций описаны показания к назначению препаратов – пробиотиков при разных заболеваниях с позиций доказательной медицины в возрастном аспекте у детей. Особое внимание уделено побочным эффектам и противопоказаниям к применению пробиотиков у детей.


Об авторах

Л. Н. Мазанкова
ГБОУ ДПО «Российская медицинская академия последипломного образования», Москва
Россия

д.м.н., проф., зав. кафедрой детских инфекционных болезней



О. В. Рыбальченко
Санкт-Петербургский государственный университет
Россия

д.б.н., проф. кафедры физиологии медицинского факультета



Е. А. Корниенко
ГБОУ ВПО «Санкт-Петербургский государственный педиатрический медицинский университет»
Россия

д.м.н., проф., зав. кафедрой гастроэнтерологии факультета послевузовского и дополнительного профессионального образования



С. Г. Перловская
ГБУЗ «Детская городская клиническая больница №9 им.Г.Н. Сперанского», Москва
Россия
врач-педиатр


Список литературы

1. Collins C.D., Purohit S., Podolsky R.H. et al. The application of genomic and proteomic technologies in predictive, preventive and personalized medicine. Vascul Pharmacol 2006; 45: 5: 258–267.

2. Бондаренко В.М., Рыбальченко О.В. Анализ профилактического и лечебного действия пробиотических препаратов с позиций новых научных технологий. Журн микробиол 2015; 2: 90–104. (Bondarenko V.M., Rybalchenko O.V. Analysis of prophylactic and therapeutic action of probiotic preparations from the standpoint of new scientific technologies. Zh Mikrobiol 2015; 2: 90–104.)

3. Lederberg J. Infectious history. Science 2000; 444: 287–293.

4. Бондаренко В.М. Обоснование и тактика назначения в медицинской практике различных форм пробиотических препаратов. Фарматека 2012; 13: 77–87. (Bondarenko V.M. The rationale and tactics of destination in medical practice of different forms of probiotic preparations. Farmateka 2012; 13: 77–87).

5. Turnbaugh P.J., Hamady M., Yatsunenko T. et al. A core gut microbiome in obese and lean twins. Nature 2009; 457: 480– 484.

6. Nielsen D.S., Mоller P.L., Rosenfeldt V. et al. Case study of the distribution of mucosa-associated Bifidobacterium species, Lactobacillus species, and other lactic acid bacteria in the human colon. Appl Environ Microbiol 2003; 69: 12: 7545–7548.

7. Парфенов А.И., Бондаренко В.М. Что нам дал вековой опыт познания симбионтной кишечной микрофлоры. Тер архив 2012; 2: 5-10. (Parfenov A.I., Bondarenko V.M. That gave us a century of experience of knowledge of symbiotic intestinal microflora. Ter arkhiv 2012; 2: 5–10).

8. Рыбальченко О.В. Электронно-микроскопическое исследование межклеточных взаимодействий микро-организмов при антагонистическом характере взаимоотношений. Микробиология 2006; 75: 4: 550–555. (Rybalchenko O.V. Electron microscopic study of intercellular interactions of microorganisms with antagonistic nature of the relationship. Mikrobiologiya 2006; 75: 4: 550–555.)

9. Лиходед В.Г., Бондаренко В.М., Гинцбург А.Л. Экзогенные и эндогенные факторы в патогенезе атеросклероза. Рецепторная теория атерогенеза. Рос кардиол журн 2010; 2: 92–96. (Likhoded V.G., Bondarenko V.M., Gintsburg A.L. Exogenous and endogenous factors in the pathogenesis of atherosclerosis. Receptor theory of atherogenesis. Ros kardiol zhurn 2010; 2: 92–96.)

10. Дисбиоз кишечника. Руководство по диагностике и лечению. Под ред. Е.И. Ткаченко, А.Н. Суворова. СПб.: СпецЛит 2007; 238. (Intestinal dysbiosis. Guidance on diagnostics and treatment. E.I. Tkachenko, A.N. Suvorov (eds). SPb.: Spetslit, 2007; 238.)

11. Шендеров Б.А. Роль персонального функционального питания в современных программах медицины антистарения. Вестн восстанов мед 2009; 3: 9–17. (Shenderov B.A. functional Role of personal power in the contemporary medicine the anti-aging. Vestn vosstanov med 2009; 3: 9–17.)

12. Рыбальченко О.В., Бондаренко В.М., Добрица В.П. Атлас ультраструктуры микробиоты кишечника человека. Изд-во СПб. ИИЦ ВМА 2008; 102. (Rybalchenko O.V., Bondarenko V.M., Dobrica V.P. Atlas of the ultrastructure of the microbiota of the human intestine. Publishing house of SPb. IRC. VMA, 2008; 102.)

13. Чернин В.В., Бондаренко В.М., Червинец В.М., Базлов С.Н. Дисбактериоз мукозной микрофлоры эзофагогастродуоденальной зоны. М: МИА 2011; 144. (Chernin V.V., Bondarenko V.M., Chervinec V.M., Bazlov S.N. Dysbacteriosis of mucosal microflora esophago-gastroduodenal zone. M: MIA 2011; 144.)

14. Бондаренко В.М., Лиходед В.Г. Распознавание комменсальной микрофлоры образраспознающими рецепторами в физиологии и патологии человека. Журн микробиол 2012; 3: 82 89. (Bondarenko V.M., Likhoded V.G. Recognition of commensal microflora by pattern recognition receptors in human physiology and pathology. Zhurn mikrobiol 2012; 3: 82–89.)

15. Ардатская М.Д., Минушкин О.Н. Современные принципы диагностики и фармакологической коррекции. Consilium Medicum Гастроэнтерология 2006; 8: 2. (Ardatskaya M.D., Minushkin O.N. Modern principles of diagnosis and pharmacological correction. Consilium Medicum Gastroehnterologiya 2006; 8: 2.)

16. Бондаренко В.М., Мацулевич Т.В. Дисбактериоз кишечника как клинико-лабораторный синдром: современное состояние проблемы. Руководство для врачей М.: ГЭОТАР–Медиа 2007; 304. (Bondarenko V.M., Matsulevitch T.V. Dysbacteriosis of the intestine as clinical and laboratory syndrome: the state of the art. The guide for physicians. M.: GEOTAR–Media, 2007: 304.)

17. FAO/WHO. Working group on drafting guidelines for the evaluation of probiotics in food. Guidelines for the evaluation of probiotics in food. 2002; http://ftp. fao. org/es/esn/food/ wgreport2.pdf

18. Probiotic bacteria in dietetic products for infants: a commentary by the ESPGHAN Committee on Nutrition. J Pediatr Gastroenterol Nutr 2004; 38: 365–374.

19. Borchers A.T. Probiotics and immunity. J Gastroenterol 2009; 4: 26–46.

20. Ng S.C., Hart A.L., Kamm M.A. et al. Mechanisms of action of probiotics: recent advances. Inflamm Bowel Dis 2009; 15: 2: 301–312.

21. Resta-Lenert S., Barrett K.E. Live probiotics protect intestinal epithelial cells from the effects of infection. Gut 2003: 52: 7: 988–997.

22. Ouwehand A., Isolauri E., Salminen S. The role of intestinal microflora for development of the immune system in early childhood. Eur J Nutr 2002; 41: 1: 132–137.

23. Duary R.K., Rajput Y.S., Batish V.K., Grover S. Assessing the adhesion of putative indigenous probiotic lactobacilli to human colonic epithelial cells. Indian J Med Res 2011; 134: 5: 664–671.

24. Yan F., Polk D.B. Probiotic bacterium prevents cytokineinduced apoptosis in intestinal epithelial cells. J Biol Chem 2002; 277: 50959–50965.

25. Braat H., Van Den B.J., Van Tol E. et al. Lactobacillus rhamnosus induces peripheral hyporesponsiveness in stimulated CD4+ T cells via modulation of dendritic cell function. Am J Clin Nutr 2004; 80: 1618–1625.

26. Fang H., Elina T., Heikki A. et al. Modulation of humoral immune response through probiotic intake. Immunol Med Microbiol 2000: 29: 47–52.

27. Szajewska H., Setty M., Mrukowicz J., Guandalini S. Probiotics in gastrointestinal diseases in children: hard and not-so-hard evidence of efficacy. J Pediatr Gastroenterol Nutr 2006; 42: 454–475.

28. Szajewska H., Karas J. Acute gastroenteritis. The COMMENT working group on acute diarrhea: Where are we now and where are we going? J Clin Gastroenterol 2014; 48: Suppl 1: S32–33.

29. Shamir R., Makhoul I.R., Etzioni A. et al. Evaluation of a diet containing probiotics and zinc for the treatment of mild diarrheal illness in children younger than one year of age. J Am Coll Nutr 2005; 24: 370–375.

30. Isolauri E., Juntunen M., Rautanen T. et al. A human Lactobacillus strain (Lactobacillus casei sp strain GG) promotes recovery from acute diarrhea in children. Pediatrics 1991; 88: 90–97.

31. Shornikova A.V., Isolauri E., Burkanova L. et al. A trial in the Karelian Republic of oral rehydration and Lactobacillus GG for treatment of acute diarrhea. Acta Paediatr 1997; 86: 460–465.

32. Guarino A., Canani R.B., Spagnuolo M.I. et al. Oral bacterial therapy reduces the duration of symptoms and of viral excretion in children with mild diarrhea. J Pediatr Gastroenterol Nutr 1997; 25: 516–519.

33. Guandalini S., Pensabene L., Zikri M.A. et al. Lactobacillus GG administered in oral rehydration solution to children with acute diarrhea: a multicenter European trial. J Pediatr Gastroenterol Nutr 2000; 30: 54–60.

34. Guarino A., Ashkenazi S., Gendrel D. et al. ESPGHAN/European Pediatric Infectious Disease evidence-based guidelines for the management of acute gastroenteritis in children in Europe, update 2014. J Pediatr Gastroenterol Nutr 2014; 59: 1: 132–152.

35. Johnston B.C., Goldenberg J.Z., Vandvik P.O. et al. Probiotics for the prevention of pediatric antibiotic-associated diarrhea. Cochrane Database Syst Rev 2011; 11: CD004827.

36. Applegate J.A., Christa L.F.W., Ramya A., Robert E.B. Systematic review of probiotics for the treatment of community- acquired acute diarrhea in children. BMC Public Health 2013; 13: Suppl 3: S16.

37. Применение пробиотиков при острых гастроэнтеритах. Consilium medicum Педиатрия 2014; 4: 53-58. (The use of probiotics in acute gastroenteritis. Consilium medicum Pediatriya 2014; 4: 53–58.)

38. Мазанкова Л. Н., Яковлева Г.Ю., Ардатская М.Д. Ротавирусная инфекция у детей раннего возраста: обоснование пробиотической терапии. Дет инф 2011; 2: 52–56. (Mazankova L.N., Yakovleva G.Y., Ardatskaya M.D. Rotavirus infection in infants: rationale of probiotic therapy. Det inf 2011; 2: 52–56.)

39. WGO. Probiotics and Prebiotics. World Gastroenterology Organization, 2011; http://www. worldgastroenterology. org/assets/export/userfiles/2012%20 Probiotics_ NEW%20 FINAL_sp. pdf.

40. Szajewska H., Ruszczyński M, Radzikowski A. Probiotics in the prevention of antibioticassociated diarrhea in children: a me ta-analysis of randomized controlled trials. J Pediatr 2006; 149: 367–372.

41. Johnston B.C., Supina A.L., Ospina M. et al. Probiotics for the prevention of pediatric antibiotic-associated diarrhea. Cochrane Database Syst Rev 2007; 2: CD004827.

42. Lynne V. McFarland. Probiotics for the Primary and Secondary Prevention of C. difficile Infections: A Meta-analysis and Systematic Review. Antibiotics 2015; 4: 160–178.

43. Saavedra J. Probiotics and infectious diarrhea. Am J Gastroenterol 2000; 95: Suppl 1: 16–18.

44. Surawicz C.M. Probiotics, antibiotic-associated diarrhea and Clostridium difficile diarrhea in humans. Best Pract Res Clin Gastroenterol 2003; 17: 775–783.

45. Malfertheiner P., Megraud F., O’Morain C.A. et al. Management of Helicobacter pylori infection – the Maastricht IV/ Florence Consensus report. Gut 2012; 61: 646–664.

46. Moayyedi P., Ford A.C., Talley N.J. et al. The efficacy of probiotics in the therapy of irritable bowel syndrome: a systemic review. Gut 2008; 64: 654–667.

47. Bin-Nun A., Bromiker R., Wilschanski M. et al. Oral probiotics prevent necrotizing enterocolitis in very low birth weight neonates. J Pediatr 2005; 147: 192–196.

48. Lin H.C., Su B.H., Chen A.C. et al. Oral probiotics reduce the incidence and severity of necrotizing enterocolitis in very low birth weight infants. Pediatrics 2005; 115: 1–4.

49. Wolvers D., Antoine J., Myllyluoma E. et al. Guidance for substantiating the evidence for beneficial effects of probiotics: prevention and management of infections by probiotics. J Nutr 2010; 140: 698–712.

50. Alfaleh K., Anabrees J., Bassler D. et al. Probiotics reduce the risk of necrotizing enterocolitis in preterm infants: a metaanalysis. Neonatology 2010; 97: 93–99.

51. Hunter C., Mary A., Peter G. et al. Effect of routine probiotic, Lactobacillus reuteri DSM 17938, use on rates of necrotizing enterocolitis in neonates with birthweight 1000 grams: a sequential analysis. BMC Pediatr 2012; 12: 142.

52. Mercenier A., Pavan S., Pot B. Probiotics as biotherapeutic agents: present knowledge and future prospects. Curr Pharm Des 2003; 9: 2: 175–191.

53. Borriello S.P., Hammes W.P., Holzapfel W. et al. Safety of probiotics that contain lactobacilli or bifidobacteria. Clin Infect Dis 2003; 36: 775–780.

54. Karpa K.D. Probiotics for Clostridium difficile diarrhea: putting it into perspective. Ann Pharmacother 2007; 41: 1284–1287.

55. Snydman D.R. The safety of probiotics. Clin Infect Dis 2008; 46: Suppl 2: 104–111.

56. Probiotics Pros and Cons. BERKELEY WELLNESS, 2014; http: www. berkeleywellness. com›…article/probiotics…andcons.

57. Kunz A.N., Noel J.M., Fairchok M.P. Two cases of Lactobacillus bacteremia during probiotic treatment of short gut syndrome. Pediatr Gastroenterol Nutr 2004; 38: 4: 457– 458.

58. Soleman N., Laferl H., Kneifel W. et al. How safe is safe? A case of Lactobacillus paracasei ssp. paracasei endocarditis and discussion of the safety of lactic acid bacteria. Scand J Infect Dis 2003; 35: 10: 759–762.

59. Salminen M.K., Tynkkynen S., Rautelin H. et al. Lactobacillus bacteremia during a rapid increase in probiotic use of Lactobacillus rhamnosus GG in Finland. Clin Infect Dis 2002; 35: 10: 1155–1160.

60. Liong M.T. Safety of probiotics: translocation and infection. Nutr Rev 2008; 66: 4: 192–202.

61. Besselink M.G., van Santvoort H.C., Buskens E. et al. Probiotic prophylaxis in predicted severe acute pancreatitis: a randomised, double-blind, placebo-controlled trial. Lancet 2008; 371: 651–659.

62. Gou S., Yang Z., Liu T., Wu H., Wang C. Use of probiotics in the treatment of severe acute pancreatitis: a systematic review and meta-analysis of randomized controlled trials. Crit Care 2014; 18: 2: R57.

63. Boyle R.J., Robins-Browne R.M., Tang M.L. Probiotic use in clinical practice: what are the risks? Am J Clin Nutr 2006; 83: 1256–1264.

64. Marteau P., Shanahan F. Basic aspects and pharmacology of probiotics an overview on pharmacokinetics, mechanisms of action and side effects. Best Pract Res Clin Gastroenterol 2003; 17: 5: 725–740.


Дополнительные файлы

Для цитирования: Мазанкова Л.Н., Рыбальченко О.В., Корниенко Е.А., Перловская С.Г. Пробиотики в педиатрии: за и против с позиции доказательной медицины. Российский вестник перинатологии и педиатрии. 2016;61(1):16-26. https://doi.org/10.21508/1027-4065-2016-61-1-17-23

For citation: Mazankova L.N., Rybalchenko O.V., Kornienko E.A., Perlovskaya S.G. Probiotics in pediatrics: Pros and cons in the context of evidence-based medicine. Rossiyskiy Vestnik Perinatologii i Pediatrii (Russian Bulletin of Perinatology and Pediatrics). 2016;61(1):16-26. (In Russ.) https://doi.org/10.21508/1027-4065-2016-61-1-17-23

Просмотров: 929

Обратные ссылки

  • Обратные ссылки не определены.


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 1027-4065 (Print)
ISSN 2500-2228 (Online)